Q-omics provides the consensus-scored HBA1 profile across patient tissues and cancer cell-line models. HBA1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HBA1 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, HBA1 RNA expression shows 13,613 significant gene co-expression associations, with the highest sampling consensus in READ. Together, these results highlight KIRC, LUAD, and READ as cancer lineages where HBA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HBA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HBA1 survival associations across molecular data types. HBA1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HBA1 RNA expression–survival associations across cancer types. High HBA1 expression shows unfavorable associations in ACC, DLBC, COAD and MESO, but favorable associations in KIRC and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HBA1 RNA expression.
This table summarizes HBA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for HBA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HBA1 shows lower tumor expression in LUAD, LUSC, THCA, STAD, BRCA and LIHC. The LUAD box plot shows higher HBA1 RNA expression in normal versus tumor tissue (log2 FC = −2.791, t-test p < 0.001).
This table shows molecular features associated with HBA1 in patient tissues and cancer cell lines. In patient samples, HBA1 shows the broadest associations at the RNA and protein expression levels, with READ recurring as the lineage with the largest associated feature set. In cancer cell lines, HBA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and PANCREAS.
